For pancreatic ductal adenocarcinoma, platinum-treated patients who had PALB2 mutations had a higher overall survival (mean: 20.1 months) compared to non-mutated controls (mean: 15.5 months), (p = 0.002). This evidence concerns the gene PALB2 and pancreatic ductal adenocarcinoma.